360
Participants
Start Date
December 30, 2014
Primary Completion Date
April 12, 2016
Study Completion Date
June 6, 2016
Spironolactone
"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
Placebo
"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
Stony Brook University Medical Center, Stony Brook
Lancaster General Hospital, Lancaster
University of Pennsylvania, Philadelphia
Jefferson Medical College, Philadelphia
Johns Hopkins Hospital, Baltimore
Duke University, Durham
Southeastern Regional Medical Center, Lumberton
Emory University School of Medicine, Atlanta
University Hospitals - Case Medical Center, Cleveland
Metro Health System, Cleveland
Cleveland Clinic, Cleveland
Mayo Clinic, Rochester
Washington University, St Louis
Saint Louis University Hospital, St Louis
Michael Debakey VA Medical Center, Houston
University of Utah School of Medicine, Salt Lake City
Utah VA Medical Center, Salt Lake City
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Boston VA Healtcare System, West Roxbury
The University of Vermont- Fletcher Allen Health Care, Burlington
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Duke University
OTHER